BioCentury
ARTICLE | Clinical News

Akcea's AKCEA-APO(a)-LRx reduces LPA levels in Phase II

October 12, 2018 6:09 PM UTC

Akcea Therapeutics Inc. (NASDAQ:AKCA) said AKCEA-APO(a)-LRx led to significant dose-dependent reductions in lipoprotein(a) (LPA) compared with placebo in a Phase II trial to reduce elevated LPA levels in patients with established cardiovascular disease. The company also said most patients who received AKCEA-APO(a)-LRx achieved LPA reductions to below the established threshold of risk for CV disease events. Akcea plans to present additional data at the American Heart Association meeting in Chicago in November.

The double-blind, international trial enrolled 286 patients with baseline LPA levels of more than three times the upper limit of normal to receive 20-60 mg AKCEA-APO(a)-LRx weekly, every other week or monthly for six months to one year...